← Leaderboards
Michael J Pucci
Achillion Pharmaceuticals, Inc.
$1,289,896
Attributed
$1,289,896
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $564.7K · FY2010–18$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$1,289,896 · 2
By mechanism
R44$989,896 · 1
R43$300,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Mycobacterium Tuberculosis”
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$267,251,837
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Kevin Urdahl · Seattle Children'S Hospital$86,597,961
- David Alland · Rutgers Biomedical And Health Sciences$70,943,567
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- William Robert Jacobs · Albert Einstein College Of Medicine$43,123,310
Research focus
Mycobacterium TuberculosisRegimenExhibitsMulti-Drug ResistancePathogenPropertyDna BiosynthesisDrug ResistanceInfectionMicrobiologyOralAnimalsAnti-Bacterial AgentsPharmaceutical PreparationsBaseCytotoxicDoseDrug KineticsExtreme Drug Resistant TuberculosisGenus MycobacteriumIn VitroIn VivoAntitubercular AgentsToxic Effect
Grant awards (3)
A Novel Gyrase Inhibitor for the Treatment of Drug-susceptible and Multidrug-resistant Mycobacterium tuberculosis Infections$425,178
R44 · FY2018 · AI · contact PI
A Novel Gyrase Inhibitor for the Treatment of Drug-susceptible and Multidrug-resistant Mycobacterium tuberculosis Infections$564,718
R44 · FY2017 · AI · contact PI
Novel Antibacterial Agents That Target DNA Replication in Mycobacterium tuberculo$300,000
R43 · FY2010 · AI · contact PI